CCM-245

CCM-245 is a novel, orally bioavailable, fourth-generation epidermal growth factor receptor (EGFR) inhibitor developed for the treatment of non-small cell lung cancer (NSCLC), particularly in metastatic settings. It is designed to overcome both on-target and off-target resistance mechanisms that limit the efficacy of third-generation EGFR inhibitors. Preclinical data presented at ASCO 2025 indicate that CCM-245 demonstrates potent activity as a monotherapy and shows high efficacy when combined with third-generation EGFR inhibitors or anti-EGFR antibodies—combinations where existing therapies fail to maintain or regress tumor volume in resistant models. The drug significantly outperforms other investigational fourth-generation EGFR inhibitors in various resistance models, suggesting strong potential for clinical application in patients with advanced NSCLC who have developed resistance to current standard-of-care treatments[1][2][6][8].